ArticleAnnals of medicine and surgery (2012)2025
Efficacy of botulinum toxin in the treatment of chronic anal fissure: a comprehensive systematic review.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute anal fissure maintains a debilitating state that produces enduring wound damage on the anal mucosa while the internal anal sphincter demonstrates increased muscle tone. This study aims to conduct a comprehensive systematic review to evaluate the efficacy of botulinum toxin (BT) in the treatment of chronic anal fissure, synthesizing current evidence from clinical trials and observational studies to guide evidence-based practice. A review of systematic research investigates the performance and security along with extended outcomes linked to BT therapy for treating chronic anal fissure by analyzing 23 clinical studies. The healing response from BT injections reaches 60%-85% without producing headache side effects commonly experienced with topical glyceryl trinitrate (GTN) medications. Lateral internal sphincterotomy (LIS) produces excellent long-term healing results in 90%-95% of cases, although it leads to fecal incontinence risks at a 5%-15% rate. Expanding BT treatment usually necessitates additional injections or surgical intervention because of its high rate of recurrence over 1-3 years (30%-40%). Combining Botox treatment with GTN administration achieves healing rates between 70% and 80%, but studies provide inconsistent research data. The optimal dosage range for BT treatment is 20-30 units, while Botox performs equally well as Dysport in achieving these results. BT provides patients who do not want surgery the benefit of being a safe, minimally invasive procedure. At the same time, LIS offers a definitive solution for patients who cannot respond to other treatments. Research must establish standardized dose instructions while improving injection methods and developing extended strategies to stop relapses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.